Ibrutinib Impurity 64 NEW

As an impurity reference standard for Ibrutinib, it features high purity and structural confirmation, which is applicable for the qualitative and quantitative analysis of impurities in drug research and development, as well as quality control, ensuring the safety and effectiveness of pharmaceuticals.

Mainly used in the research and development of Ibrutinib-related drugs, quality control during production (such as impurity limit detection and analytical method validation), and can also be applied to the study of drug stability and identification of degradation products.

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor widely used in the treatment of B-cell malignancies (such as chronic lymphocytic leukemia, mantle cell lymphoma, etc.). In drug research, development, and production, the control of impurities is a key link to ensure drug quality. Therefore, the research and application of Ibrutinib impurity reference standards are of great significance for drug quality evaluation.

At present, studies on Ibrutinib impurities mainly focus on the synthesis, structural characterization of impurities, and their impact on drug safety. As a specific impurity, Ibrutinib Impurity 64 has become an important part of drug quality research in terms of its preparation method and residual control in drugs. Relevant researches aim to further improve the quality standards and production processes of Ibrutinib